AIDS Clinical Trial
Official title:
A Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV treatment--a Multicenter, Randomized, Double-blind, Double-simulation, Positive Control Trial
The primary objective of this trial was to evaluate the safety and preliminary evaluation of Azvudine tablets (FNC) in combination with reverse transcriptase inhibitors therapy in treatment-naive patients with HIV infection.; the secondary objective is to explore the effective dose of clinical use of Azvudine (FNC) tablets .
Azvudine (FNC), a new class I drug with independent intellectual property rights, is a novel
nucleoside reverse transcriptase inhibitor with good inhibitory activity against HIV-1 and
obtained the National Medical Products Administration(NMPA) approved for clinical research.
In this trial, 172 patients who had not received anti-HIV treatment were enrolled, including
FNC4mg group, FNC3mg group, FNC2mg group, and 3TC control group, 43 cases, 5 research
centers, and each research center was simultaneously engaged and competing. The enrolled
subjects underwent 7 visits including baseline visits, and HIV -1RNA and CD4 cell counts were
tested and statistically analyzed for each visit.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
| Not yet recruiting |
NCT03661203 -
Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
|
||
| Completed |
NCT02711878 -
Healing Hearts and Mending Minds in Older Adults Living With HIV
|
N/A | |
| Completed |
NCT02606344 -
Effect of a Micro-finance-based Intervention for the Prevention of Intimate-partner Violence and HIV
|
N/A | |
| Completed |
NCT01053598 -
Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting
|
N/A | |
| Completed |
NCT01348308 -
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT01237366 -
Study Targeting Affect Regulation
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT00951795 -
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
|
N/A | |
| Completed |
NCT00740389 -
TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.
|
Phase 1 | |
| Withdrawn |
NCT00347750 -
Pharmacokinetics and Pharmacodynamics of an Anti-HIV Drug in Israeli Ethiopian and Non-Ethiopian Populations
|
Phase 3 | |
| Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
| Withdrawn |
NCT00340223 -
HLA-B35 Alleles and AIDS
|
N/A | |
| Completed |
NCT01084395 -
Reducing HIV Risk Among Mexican Youth
|
N/A | |
| Completed |
NCT00144352 -
In-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Adults
|
Phase 4 | |
| Completed |
NCT00202241 -
The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS
|
N/A | |
| Completed |
NCT00341172 -
The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis
|
||
| Recruiting |
NCT06145841 -
Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies
|
||
| Completed |
NCT03633721 -
Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women
|
Phase 2 | |
| Completed |
NCT04567693 -
Reducing Time to Spaced-out Appointments for Newly-diagnosed People Living With HIV
|
N/A | |
| Completed |
NCT03023033 -
Supporting Attendance for Facility Delivery and Infant Health
|
N/A |